Indiplon
 |
|
|---|---|
| Systematic (IUPAC) name | |
| N-methyl-N-[3-[3-(thiophene-2-carbonyl) pyrazolo[5,1-b]pyrimidin-7-yl]phenyl]acetamide |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Schedule IV (US) |
| Routes | Oral |
| Identifiers | |
| CAS number | 325715-02-4  |
| ATC code | None |
| PubChem | CID 6450813 |
| ChemSpider | 4953363  |
| UNII | 8BT63DA42E |
| KEGG | D02640 |
| ChEMBL | CHEMBL262075 |
| Chemical data | |
| Formula | C20H16N4O2S |
| Mol. mass | 376.0993 |
| SMILES | eMolecules & PubChem |
|
|
 (what is this?) (verify) |
|
Indiplon (INN and USAN) is a nonbenzodiazepine, hypnotic sedative being developed in 2 formulations - an immediate release product for sleep onset and a modified-release version for sleep maintenance.
Contents |
[edit] Mode of action
Indiplon is said to work by enhancing the action of the inhibitory neurotransmitter GABA, like most other nonbenzodiazepine sedatives. It primarily binds to the α1 subunits of the GABAA receptors in the brain.[1]
[edit] Availability
Indiplon was originally scheduled for release to doctors and pharmacies sometime in 2007, most likely in the springtime of that year, which is when Sanofi-Aventis' popular sleep aid, zolpidem, lost its patent rights in the United States and thus became available to patients as a much less expensive generic. Neurocrine Biosciences had planned to comarket indiplon in the US with Pfizer. However, following the issuing of a nonapprovable letter for the modified-release 15 mg formulation and an approvable letter (with stipulations) for the 5 mg and 10 mg immediate-release version by the FDA (May 2006), Pfizer decided to end its relationship with Neurocrine.[citation needed]
On December 13, 2007, Neurocrine announced that the FDA deemed their new drug application (NDA) 'approvable'.[2] The 2007 Approvable Letter does not reference the setbacks seen previously in the May 2006 Approvable Letter, bringing the availability of indiplon one step closer to the consumer.[2]
The planned brand name has not yet been revealed to the public. The NDA was initially approved by the FDA in 1998,[citation needed] and since then, Neurocrine has been conducting clinical trials, with purportedly satisfactory results.[citation needed]
Neurocrine's website is currently stating that they have discontinued development of indiplon in the United States, raising doubts about whether it will ever be brought to market.[3]
[edit] References
- ^ Petroski RE, Pomeroy JE, Das R et al. (April 2006). "Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors" (PDF). J. Pharmacol. Exp. Ther. 317 (1): 369–77. doi:10.1124/jpet.105.096701. PMID 16399882. http://jpet.aspetjournals.org/cgi/content/full/317/1/369.
- ^ a b "Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA" (Press release). Neurocrine Biosciences, Inc.. 2007-12-13. http://www.drugs.com/nda/indiplon_071213.html. Retrieved 2007-12-13.
- ^ "Neurocrine Biosciences: Pipeline: Additional Pipeline Programs". Neurocrine Biosciences. 2007. Programs Subject to Regulatory Review. http://www.neurocrine.com/index.cfm?navId=25. Retrieved 18 July 2011. "After receipt of the 2007 FDA Approvable Letter, we ceased all indiplon clinical development activities in the United States ..."
[edit] External links
- Neurocrine's drug pipeline page referencing indiplon
- 2004 press release announcing Neurocrine's new product, Indiplon
- Pfizer
- GenomeNet Entry: D02640
